Van Berkom & Associates Inc. lifted its holdings in Chemed Co. (NYSE:CHE – Free Report) by 12.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 129,960 shares of the company’s stock after buying an additional 14,141 shares during the quarter. Chemed makes up about 2.1% of Van Berkom & Associates Inc.’s holdings, making the stock its 26th biggest holding. Van Berkom & Associates Inc. owned 0.86% of Chemed worth $70,514,000 at the end of the most recent quarter.
Several other institutional investors also recently modified their holdings of the business. Rise Advisors LLC purchased a new stake in Chemed in the first quarter worth about $26,000. GAMMA Investing LLC increased its position in Chemed by 34.4% during the 2nd quarter. GAMMA Investing LLC now owns 86 shares of the company’s stock valued at $47,000 after buying an additional 22 shares in the last quarter. Principal Securities Inc. purchased a new position in Chemed during the fourth quarter valued at $51,000. Mather Group LLC. bought a new stake in Chemed in the first quarter worth $67,000. Finally, EntryPoint Capital LLC grew its stake in shares of Chemed by 14.0% in the first quarter. EntryPoint Capital LLC now owns 147 shares of the company’s stock worth $94,000 after acquiring an additional 18 shares during the last quarter. 95.85% of the stock is currently owned by institutional investors.
Insider Transactions at Chemed
In other Chemed news, CEO Kevin J. Mcnamara sold 2,000 shares of the company’s stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $569.63, for a total value of $1,139,260.00. Following the completion of the sale, the chief executive officer now owns 105,735 shares in the company, valued at $60,229,828.05. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other Chemed news, CEO Kevin J. Mcnamara sold 2,000 shares of the firm’s stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $569.63, for a total transaction of $1,139,260.00. Following the sale, the chief executive officer now directly owns 105,735 shares of the company’s stock, valued at $60,229,828.05. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director George J. Walsh III sold 200 shares of the stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $577.95, for a total value of $115,590.00. Following the sale, the director now owns 3,446 shares of the company’s stock, valued at approximately $1,991,615.70. The disclosure for this sale can be found here. Insiders have sold 5,315 shares of company stock worth $3,006,573 in the last quarter. Company insiders own 3.32% of the company’s stock.
Chemed Stock Down 0.3 %
Chemed (NYSE:CHE – Get Free Report) last issued its earnings results on Wednesday, July 24th. The company reported $5.47 earnings per share for the quarter, missing analysts’ consensus estimates of $5.59 by ($0.12). The business had revenue of $595.88 million during the quarter, compared to analysts’ expectations of $599.20 million. Chemed had a return on equity of 29.21% and a net margin of 12.88%. Chemed’s quarterly revenue was up 7.6% compared to the same quarter last year. During the same period last year, the firm posted $4.71 EPS. As a group, research analysts predict that Chemed Co. will post 21.77 EPS for the current year.
Chemed Increases Dividend
The firm also recently declared a quarterly dividend, which was paid on Friday, August 30th. Stockholders of record on Monday, August 12th were given a dividend of $0.50 per share. The ex-dividend date was Monday, August 12th. This represents a $2.00 annualized dividend and a dividend yield of 0.35%. This is a positive change from Chemed’s previous quarterly dividend of $0.40. Chemed’s dividend payout ratio is presently 10.76%.
Analyst Ratings Changes
Separately, Royal Bank of Canada dropped their price target on shares of Chemed from $712.00 to $697.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 21st.
About Chemed
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.
Recommended Stories
- Five stocks we like better than Chemed
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- 4 Reasons to Consider Adding General Mills to Your Portfolio
- P/E Ratio Calculation: How to Assess Stocks
- NIO’s Big Play: How Battery Swapping Stations Can Drive Growth
- 10 Best Airline Stocks to Buy
- Guidewire’s 10% Upside Is an Easy Target for Its Stock to Reach
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.